Dublin, Nov. 06, 2017 -- The "Ulcerative Colitis Forecast in 12 Major Markets 2017-2027" report has been added to Research and Markets' offering.
Ulcerative Colitis (UC) is an inflammatory bowel disease (IBD) causing chronic inflammation in the colon, and is treated as an autoimmune disease. While sharing some features with Crohn's disease, UC is an intermittent disease with periods of symptoms interspersed with asymptomatic periods (generally induced by response to treatment). The disease involves the rectum up to the colon and is classified according to length of colon affected.
This report provides the current prevalent population for Ulcerative Colitis across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Brazil, Japan, China, India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight, several of the main symptoms and co-morbidities of Ulcerative Colitis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Ulcerative Colitis include:
- Anaemia
- Gastritis
- Colorectal cancer
- Osteoporosis
- Complications from surgery
- Pouchitis
- Toxic megacolon
- Extra-intestinal features (e.g. primary sclerosing cholangitis, erythema nodosum)
Reasons to Buy:
- Able to quantify patient populations in global Ulcerative Colitis's market to target the development of future products, pricing strategies and launch plans
- Gain further insight into the prevalence of the subdivided types of Ulcerative Colitis and identify patient segments with high potential
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries
- Provide a level of understanding on the impact from specific co-morbid conditions on Ulcerative Colitis's prevalent population
- Identify sub-populations within Ulcerative Colitis which require treatment
- Gain an understanding of the specific markets that have the largest number of Ulcerative Colitis patients
Key Topics Covered:
- Introduction
- Cause of the Disease
- Risk Factors & Prevention
- Diagnosis of the Disease
- Variation by Geography/Ethnicity
- Disease Prognosis & Clinical Course
- Key Comorbid Conditions / Features Associated With the Disease
- Methodology for Quantification of Patient Numbers
- Top-Line Prevalence for Ulcerative Colitis
- Features of Ulcerative Colitis Patients
- Associated Conditions of Ulcerative Colitis
- Abbreviations Used in the Report
- Other Publications
- Online Patient-Based Databases
- Patient-Based Offering
- Online Pricing Data & Platforms
- References
- Appendix
List of Tables
Table 1. Severity Index for Adult Uc Patients
Table 2. Prevalence of Ulcerative Colitis, Total (000S)
Table 3. Prevalence of Ulcerative Colitis, Males (000S)
Table 4. Prevalence of Ulcerative Colitis, Females (000S)
Table 5. Extent of Involvement at Diagnosis in Ulcerative Colitis Patients, Total (000S)
Table 6. Severity of Ulcerative Colitis at Diagnosis in Patients, Total (000S)
Table 7. Smoking Status of Ulcerative Colitis Patients, Total (000S)
Table 8. Ulcerative Colitis Patients With Family History of Uc, Total (000S)
Table 9. Prevalence of Osteoporosis in Ulcerative Colitis Patients, Total (000S)
Table 10. Prevalence of Peripheral Arthritis in Ulcerative Colitis Patients, Total (000S)
Table 11. Prevalence of Ankylosing Spondylitis in Ulcerative Colitis Patients, Total (000S)
Table 12. Prevalence of Oral Ulcerations in Ulcerative Colitis Patients, Total (000S)
Table 13. Prevalence of Pyoderma Gangrenosum in Ulcerative Colitis Patients, Total (000S)
Table 14. Prevalence of Primary Sclerosing Cholangitis in Ulcerative Colitis Patients, Total (000S)
Table 15. Prevalence of Gastritis in Ulcerative Colitis Patients, Total (000S)
Table 16. Type of Gastritis in Ulcerative Colitis Patients, Total (000S)
Table 17. Prevalence of Anaemia in Ulcerative Colitis Patients, Total (000S)
Table 18. Prevalence of Elevated Crp in Ulcerative Colitis Patients, Total (000S)
Table 19. Prevalence of Elevated Esr in Ulcerative Colitis Patients, Total (000S)
Table 20. Abbreviations and Acronyms Used in the Report
Table 21. Usa Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Males (000S)
Table 22. Usa Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Females (000S)
Table 23. Canada Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Males (000S)
Table 24. Canada Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Females (000S)
Table 25. France Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Males (000S)
Table 26. France Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Females (000S)
Table 25. Germany Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Males (000S)
Table 26. Germany Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Females (000S)
Table 27. Italy Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Males (000S)
Table 28. Italy Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Females (000S)
Table 29. Spain Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Males (000S)
Table 30. Spain Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Females (000S)
Table 31. United Kingdom Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Males (000S)
Table 32. United Kingdom Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Females (000S)
Table 31. Russia Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Males (000S)
Table 32. Russia Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Females (000S)
Table 33. Brazil Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Males (000S)
Table 34. Brazil Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Females (000S)
Table 35. Japan Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Males (000S)
Table 36. Japan Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Females (000S)
Table 35. China Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Males (000S)
Table 36. China Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Females (000S)
Table 35. India Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Males (000S)
Table 36. India Prevalence of Ulcerative Colitis by 5-Yr Age Cohort, Females (000S)
For more information about this report visit https://www.researchandmarkets.com/research/55mxjc/ulcerative
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Gastrointestinal Drugs


GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
How Marco Pharma International Preserves German Homeopathic Traditions in America
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems
FTC Questions Apple News Over Alleged Bias Against Conservative Media
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 



